Atherogenics stock leaps on heart trial data
676802
Shares of Atherogenics Inc. (AGIX.O: Quote, Profile, Research) leaped 82 percent in electronic trading before the market opened on Tuesday following the release of data showing
735577
Shares in OSI Pharmaceuticals (OSIP :Nasdaq - news - research) and Genentech (DNA :Nasdaq - news - research) jumped Friday after AstraZeneca (AZN :NYSE - news - research) said new medical data showed its lung cancer drug Iressa provided no survival
184796
Shares of OSI Pharmaceuticals Inc.  OSIP.O jumped 13 percent in pre-market trade on Monday after  the company's experimental drug was shown to prolong the lives  of patients with cancer of the pancreas.
87010
New data are due out on a promising cholesterol drug. But there are doubters.
644720
A recap of some of the hottest stocks on the market.
459907
Introgen Therapeutics Inc., a gene  therapy company, on Thursday said its experimental breast  cancer treatment showed promise in a mid-stage clinical trial,  driving its shares up 24 percent.
623932
The lead drug gains another use -- just not the one investors expected.
683607
AtheroGenics announces the path forward for its lead drug.
160226
The contract drug research company shares surged as the firm showed signs of new life.
59608
Standard &amp; Poor&#39;s Equity Research reiterated a &quot;hold&quot; rating and $68 target price on Biogen Idec (nasdaq: BIIB - news - people ), saying the anticipated success of the company&#39;s Antegren drug is largely factored into the share price.
414602
Stock falls on news treatment failed a mid-stage trial, company will cease developing drug. NEW YORK  - AtheroGenics Inc.
633781
Schering-Plough said that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
84259
Shares of VaxGen Inc. surged 17 percent Friday after the government said it would buy 75 million doses of a new generation anthrax vaccine under an $877.
119423
Shares of AtheroGenics Inc. AGIX.O  soared 82 percent before the bell on Tuesday, a day after the  pharmaceutical company announced positive interim results from  a study on an anti-inflammatory agent.
583318
Science & environment: Ben Goldacre: Wondrous, amazing, buy-more-now positive results of even more trials of fish oils have started appearing all over the media.
519863
The company faces a pivotal clinical trial.
449617
Shares of OSI Pharmaceuticals Inc. (OSIP.O: Quote, Profile, Research) jumped 13 percent in pre-market trade on Monday after the company&#39;s experimental drug was shown to prolong the lives of patients with cancer of the pancreas.